Source: Njoku JC. Influenza. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 10th ed. New York, NY: McGraw-Hill; 2017. http://accesspharmacy.mhmedical.com/content.aspx?bookid=1861§ionid=146071550. Accessed March 25, 2017.
Hemagglutinin allows virus to enter host cells.
Incubation period: 1–7 days (average 2 days)
Immunity occurs through antibody development directed at surface antigens, particularly hemagglutinin.
Seasonal epidemics result in 25–50 million cases, ~200,000 hospitalizations, and >30,000 deaths each year in the United States.
Overall, more people die of influenza than of any other vaccine-preventable illness.
Deaths often result from.
Types A, B, and C affect many species.
TABLE 1.Comparison of Trivalent (TIV) and Live-Attenuated Influenza Vaccine (LAIV) ||Download (.pdf) TABLE 1. Comparison of Trivalent (TIV) and Live-Attenuated Influenza Vaccine (LAIV)
|Characteristic ||TIV ||LAIV |